Legalisation and Liberalisation of Cannabis: The Benefits and Drawbacks of the Global Trend


  • OA Fasesan



Cannabis sativa is a complex domesticated plant that has an unstable taxonomy. It is the most utilised illicit substance that has gained prominence in some parts of the world as it is used for therapeutic and recreational purposes. C. Sativa has also been used to manage numerous medical conditions since antiquity. The pharmacological benefits of C. sativa are still subject to intense research due to inconsistent outcomes. C. sativa, like other psychoactive substances, has both medical and psychological side effects. Despite the lack of knowledge, medical practitioners continue to recommend this substance. This review aims to highlight the effects of legalisation and liberalisation on the global trend of cannabis use. A search was conducted on Google Scholar and Medline from 2012 to date. The results showed that cannabis was found to be effective in the management of some medical conditions, though more work is required. Recreational use is rising due to a reduced perception of harm and the availability of more potent species. Cannabis use persists despite the several medical and psychological side effects. It is concluded that there is a shortage of information on the safety and pharmacological properties of C. sativa, and more work is required.


Marshall K, Gowing L, Ali R, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database of Systematic Reviews 2014, Issue 12. Art. No.: CD008940.

Fischer B, Robinson T, Bullen C, Curran V, Jutras-Aswad D, Medina-Mora ME, et al. Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. Int J Drug Policy 2022; 99: 103381.

Hill KP, Palastro MD, Johnson B, Ditre JW. Cannabis and Pain: A Clinical Review. Cannabis Cannabinoid Res 2017; 2: 96–104.

UN. United Nations Office on Drugs and Crime, World Drug Report 2017. U N Publ [Internet]. 2017; Available from:

Nielsen S, Gowing L, Sabioni P, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Drugs and Alcohol Group, editor. Cochrane Database Syst Rev [Internet]. 2019 28 January [cited 2022 6 August]; 2020(3). Available from:

United Nations, United Nations Office on Drugs and Crime. World drug report, 2013. [Internet]. New York: United Nations; 2013 [cited 2022 20 August]. Available from:

SAMHSA. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS): 1996-2006. National Admissions to Substance Abuse Treatment Services [Internet]. Rockville, Maryland, USA; 2008 Jul [cited 2021 20 August] p. 201. (S-43). Report No.: 08–4347. Available from:

Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse Health Effects of Marijuana Use. N Engl J Med 2014; 370: 2219–2227.

Copeland J, Clement N, Swift W. Cannabis use, harms and the management of cannabis use disorder. Neuropsychiatry 2014; 4: 55–63.

Hall W, Lynskey M. Assessing the public health impacts of legalising recreational cannabis use: the US experience. World Psychiatry 2020; 19: 179–186.

Spindle TR, Cone EJ, Schlienz NJ, Mitchell JM, Bigelow GE, Flegel R, et al. Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use Cannabis: A Crossover Trial. JAMA Netw Open. 2018; 1: e184841.

Spindle TR, Bonn-Miller MO, Vandrey R. Changing landscape of cannabis: novel products, formulations, and methods of administration. Curr Opin Psychol 2019; 30: 98–102.

Philpot LM, Ebbert JO, Hurt RT. A survey of the attitudes, beliefs and knowledge about medical cannabis among primary care providers. BMC Fam Pract 2019; 20: 17.

Vigil JM, Stith SS, Adams IM, Reeve AP. Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study. Vrana KE (Editor). PLoS ONE 2017; 12: e0187795.

Abuhasira R, Shbiro L, Landschaft Y. Medical use of cannabis and cannabinoids containing products – Regulations in Europe and North America. Eur J Intern Med 2018; 49: 2–6.

Rahn B, Pearson BJ, Trigiano RN, Gray DJ. The Derivation of Modern Cannabis Varieties. Crit Rev Plant Sci 2016; 35: 328–348.

United Nations Office on Drugs and Crime. World drug report 2014. Vienna: United Nations Office on Drugs and Crime; 2014.

Pollio A. The Name of Cannabis: A Short Guide for Nonbotanists. Cannabis Cannabinoid Res 2016; 1: 234–238.

Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol 2012; 2: 241–254.

Clarke RC, Merlin MD. Cannabis Domestication, Breeding History, Present-day Genetic Diversity, and Future Prospects. Crit Rev Plant Sci 2016; 35: 293–327.

Coombes R. Cannabis regulation: high time for change? BMJ. 2014; 348: g3382–g3382.

Freeman TP, Winstock AR. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med 2015; 45: 3181–3189.

Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects: Phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 2011; 163: 1344–1364.

Aliferis KA, Bernard-Perron D. Cannabinomics: Application of Metabolomics in Cannabis (Cannabis sativa L.) Research and Development. Front Plant Sci 2020; 11: 554.

Savage SR, Romero-Sandoval A, Schatman M, Wallace M, Fanciullo G, McCarberg B, et al. Cannabis in Pain Treatment: Clinical and Research Considerations. J Pain 2016; 17: 654–668.

Monthony AS, Page SR, Hesami M, Jones AMP. The Past, Present and Future of Cannabis sativa Tissue Culture. Plants. 2021 19 January;10(1):185.

Pisanti S, Bifulco M. Medical Cannabis: A plurimillennial history of an evergreen. J Cell Physiol 2019; 234: 8342–8351.

Crocq MA. History of cannabis and the endocannabinoid system. Dialogues Clin Neurosci 2020; 22: 223–228.

Wellcome Trust Centre for the History of Medicine. The medicalisation of cannabis: the transcript of a Witness Seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 24 March 2009. Crowther SM, Reynolds LA, Tansey EM, editors. London: Wellcome Trust Centre for the History of Medicine at UCL; 2010. 106 p. (Wellcome witnesses to twentieth century medicine). ISBN: 978-0-85484-129-5

Watson SJ. Marijuana and Medicine: Assessing the Science Base: A Summary of the 1999 Institute of Medicine Report. Arch Gen Psychiatry 2000; 57: 547–552.

Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem 2015; 23: 1377–1385.

Mechoulam R, Gaoni Y. A Total Synthesis of dl-Δ 1 -Tetrahydrocannabinol, the Active Constituent of Hashish. J Am Chem Soc 1965; 87: 3273–3275.

Pertwee RG. Cannabinoid pharmacology: the first 66 years: Cannabinoid pharmacology. Br J Pharmacol 2006; 147: S163–S171.

Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor. Science 1992; 258: 1946–1949.

Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci 2018; 19: 833.

Jarvis S, Rassmussen S, Winters B. Role of the Endocannabinoid System and Medical Cannabis. J Nurse Pract 2017; 13: 525–531.

Gertsch J, Pertwee RG, Di Marzo V. Phytocannabinoids beyond the Cannabis plant - do they exist? : Phytocannabinoids beyond the Cannabis plant. Br J Pharmacol 2010; 160: 523–529.

Russo EB. History of Cannabis and Its Preparations in Saga, Science, and Sobriquet. Chem Biodivers 2007; 4: 1614–1648.

Potter DJ. A review of the cultivation and processing of cannabis (Cannabis sativa L.) for production of prescription medicines in the UK: Cultivation and processing of cannabis for production of prescription medicines. Drug Test Anal 2014; 6: 31–38.

Freeman TP, Morgan CJA, Hindocha C, Schafer G, Das RK, Curran HV. Just say ‘know’: how do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints?: Cannabis potency. Addiction 2014; 109: 1686–1694.

Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJA, et al. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: A randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol 2015; 25: 325–334.

Crippa JAS, Hallak JEC, Machado-de-Sousa JP, Queiroz RHC, Bergamaschi M, Chagas MHN, et al. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report: CBD and cannabis withdrawal. J Clin Pharm Ther 2013; 38: 162–164.

Sarris J, Sinclair J, Karamacoska D, Davidson M, Firth J. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry 2020; 20: 24.

Landa L, Jurica J, Sliva J, Pechackova M, Demlova R. Medical cannabis in the treatment of cancer pain and spastic conditions and options of drug delivery in clinical practice. Biomed Pap 2018; 162: 18–25.

Reddy D. The utility of Cannabidiol in the Treatment of Refractory Epilepsy. Clin Pharmacol Ther 2017; 101: 182–184.

Cash MC, Cunnane K, Fan C, Romero-Sandoval EA. Mapping cannabis potency in medical and recreational programs in the United States. Largent-Milnes T (Editor). PLoS ONE 2020; 15: e0230167.

Sommano SR, Chittasupho C, Ruksiriwanich W, Jantrawut P. The Cannabis Terpenes. Molecules 2020; 25: 5792.

Wilsey B, Deutsch R, Samara E, Marcotte T, Barnes A, Huestis M, et al. A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporised cannabis. J Pain Res 2016; 9: 587–598.

Wallace M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H, et al. Dose-dependent Effects of Smoked Cannabis on Capsaicin-induced Pain and Hyperalgesia in Healthy Volunteers. Anesthesiology 2007; 107: 785–796.

Bridgeman MB, Abazia DT. Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting. P T Peer-Rev J Formul Manag 2017; 42: 180–188.

Young People’s Statistics from the National Drug Treatment Monitoring System (NDTMS): 1 April 2016 to 31 March 2017 [Internet]. Available from:

Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J. Cannabis use and cannabis use disorders among individuals with mental illness. Compr Psychiatry 2013; 54: 589–598.

Eurosurveillance editorial team. The European Monitoring Centre for Drugs and Drug Addiction publishes the European Drug Report 2013: trends and developments. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull 2013; 18: 20491.

Van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M. Predicting the transition from frequent cannabis use to cannabis dependence: A three-year prospective study. Drug Alcohol Depend 2013; 133: 352–359.

Johnson EC, Demontis D, Thorgeirsson TE, Walters RK, Polimanti R, Hatoum AS, et al. A large-scale genome-wide association study meta-analysis of cannabis use disorder. Lancet Psychiatry 2020; 7: 1032–1045.